IL-6 and PPARγ signalling in human PC-3 prostate cancer cells

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 2331-2337

  Pitulis, Nea ^a   Papageorgiou, Efstathia ^a   Tenta, Roxane ^b   Lembessis, Peter ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HAROKOPIO UNIVERSITY   (Greece)

Author keywords

15dPGJ2; IL 6; PC 3 cells; PPAR ; Prostate cancer; Stat3

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; STAT PROTEIN; TRYPAN BLUE; MESSENGER RNA; STAT3 PROTEIN;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY TEST; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

BLOTTING, WESTERN; CELL PROLIFERATION; HUMANS; INTERLEUKIN-6; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PPAR GAMMA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 67650904952     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Isaacs JT: The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 26: 263-273, 1999.
2. Abate-Shen C, Shen MM: Molecular genetics of prostate cancer. Genes Dev 14: 2410-2434, 2000.
3. Pilat MJ, Kamradt JM, Pienta KJ: Hormone resistance in prostate cancer. Cancer Metastasis Rev 17: 373-381, 1998.
4. Tenta R, Tiblalexi D, Sotiriou E, Lembessis P, Manoussakis M, Koutsilieris M: Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate 59: 120-131, 2004. (Pubitemid 38481223)
5. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP: Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41: 127-133, 1999. (Pubitemid 29446967)
6. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H and Murai M: Serum interleukin-6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6: 2702-2706, 2000. (Pubitemid 30482107)
7. Chung TD, Yu JJ, Spiotto MT, Bartkowski M and Simons JW: Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38: 199-207, 1999. (Pubitemid 29054936)
8. Okamoto M, Lee C and Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57: 141-146, 1997. (Pubitemid 27020343)
9. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY and Simons JW: Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45: 542-549, 1995.
10. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F and de la Taille A: The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol 25: 477-489, 2007.
11. Lou W, Ni Z, Dyer K, Tweardy DJ and Gao AC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42: 239-242, 2000. (Pubitemid 30080423)
12. Maliner-Stratton MS, Klein RD, Udayakumar TS, Nagle RB and Bowden GT: Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP. Neoplasia 3: 509-520, 2001. (Pubitemid 33151017)
13. Shida Y, Igawa T, Hakariya T, Sakai H and Kanetake H: p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion. Biochem Biophys Res Commun 353: 744-749, 2007. (Pubitemid 46048733)
14. Koul S, Huang M, Chaturvedi L, Meacham RB and Koul HK: p42/p44 Mitogen-activated protein kinase signal transduction pathway regulates interleukin-6 expression in PC3 cells, a line of hormone-refractory prostate cancer cells. Ann NY Acad Sci 1030: 253-257, 2004. (Pubitemid 40378920)
15. Zerbini LF, Wang Y, Cho JY and Libermann TA: Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin-6 expression in prostate cancer. Cancer Res 63: 2206-2215, 2003. (Pubitemid 36538628)
16. 1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 257: 609-614, 1999.
17. Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK and Kuo ML: Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 60: 120-129, 2004. (Pubitemid 38758577)
18. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20, 2003. (Pubitemid 37046923)
19. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F and Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334(Pt 2): 297-314, 1998. (Pubitemid 28448572)
20. Spiotto MT and Chung TD: STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 42: 186-195, 2000. (Pubitemid 30080417)
21. Spiotto MT and Chung TD: STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 42: 88-98, 2000. (Pubitemid 30056640)
22. Smith ND, Schulze-Hoepfner FT, Veliceasa D, Filleur S, Shareef S, Huang L, Huang XM and Volpert OV: Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism. J Urol 179: 2427-2434, 2008.
23. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W and Culig Z: Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol 169: 2199-2208, 2006. (Pubitemid 351181978)
24. Yang Y, Ikezoe T, Takeuchi T, Adachi Y, Ohtsuki Y, Takeuchi S, Koeffler HP and Taguchi H: HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 96: 425-433, 2005.
25. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L and Nevalainen MT: Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 172: 1717-1728, 2008. (Pubitemid 351793362)
26. Ni Z, Lou W, Leman ES and Gao AC: Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 60: 1225-1228, 2000. (Pubitemid 30151988)
27. Hellsten R, Johansson M, Dahlman A, Dizeyi N, Sterner O and Bjartell A: Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate 68: 269-280, 2008. (Pubitemid 351273056)
28. Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, Trock BJ, Thouta R, Raj MH and Rao PN: Differential effects of leptin on the invasive potential of androgen-dependent and -independent prostate carcinoma cells. J Biomed Biotechnol 2008: 163902, 2008.
29. Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5: 419-429, 2004. (Pubitemid 38878045)
30. Papageorgiou E, Pitulis N, Msaouel P, Lembessis P and Koutsilieris M: The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines. Expert Opin Ther Targets 11: 1071-1085, 2007. (Pubitemid 47240680)
31. Lennon AM, Ramauge M, Dessouroux A and Pierre M: MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-delta(12-14)-prostaglandin J(2) and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species. J Biol Chem 277: 29681-29685, 2002.
32. Gardner OS, Dewar BJ, Earp HS, Samet JM and Graves LM: Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J Biol Chem 278: 46261-46269, 2003. (Pubitemid 37452196)
33. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM and Kantoff PW: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97: 10990-10995, 2000. (Pubitemid 30751266)
34. 2. Cell Growth Differ 11: 49-61, 2000.
35. Jiang C, Ting AT and Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86, 1998. (Pubitemid 28079219)
36. Wung BS, Wu CC, Hsu MC and Hsieh CW: 15-Deoxy-delta(12,14)-prostaglandin J(2) suppresses IL-6-induced STAT3 phosphorylation via electrophilic reactivity in endothelial cells. Life Sci 78: 3035-3042, 2006.
37. 2 inhibits IL-6-induced Stat3 phosphorylation in lymphocytes. Exp Mol Med 37: 179-185, 2005. (Pubitemid 40992732)
38. 2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem 278: 14747-14752, 2003. (Pubitemid 36799798)
39. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S and Koeffler HP: Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 60: 5494-5498, 2000. (Pubitemid 30761263)
40. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I and Koeffler HP: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352, 1998. (Pubitemid 28371075)
41. Papageorgiou E, Pitulis N, Manoussakis M, Lembessis P and Koutsilieris M: Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med 14: 403-411, 2008.
42. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE and Stark GR: Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 21: 1396-1408, 2007. (Pubitemid 46871042)
43. Yang J and Stark GR: Roles of unphosphorylated STATs in signaling. Cell Res 18: 443-451, 2008.